Lipid–polymer hybrid nanoparticle-mediated therapeutics delivery: advances and challenges

Rajendran J.C. Bose; Rramaswamy Ravikumar; Vengadeshprabu Karuppagounder; Devasier Bennet; Sabarinathan Rangasamy; Rajarajan A. Thandavarayan

doi:10.1016/j.drudis.2017.05.015

Lipid–polymer hybrid nanoparticle-mediated therapeutics delivery: advances and challenges

Rajendran J.C. Bose, Rramaswamy Ravikumar, Vengadeshprabu Karuppagounder, Devasier Bennet, Sabarinathan Rangasamy, Rajarajan A. Thandavarayan

Research output: Contribution to journal › Review article › peer-review

63 Scopus citations

Abstract

With rapid advances in nanomedicine, lipid–polymer hybrid nanoparticles (LPHNPs) have emerged as promising nanocarriers for several biomedical applications, including therapeutics delivery and biomedical imaging. Significant research has been dedicated to biomimetic or targeting functionalization, as well as controlled and image-guided drug-release capabilities. Despite this research, the clinical translation of LPHNP-mediated therapeutics delivery has progressed incrementally. In this review, we discuss the recent advances in and challenges to the development and application of LPHNPs, present examples to demonstrate the advantages of LPHNPs in therapeutics delivery and imaging applications, and discuss the translational obstacles to LPHNP technology.

Original language	English (US)
Pages (from-to)	1258-1265
Number of pages	8
Journal	Drug Discovery Today
Volume	22
Issue number	8
DOIs	https://doi.org/10.1016/j.drudis.2017.05.015
State	Published - Aug 2017

ASJC Scopus subject areas

Pharmacology
Drug Discovery

Access to Document

10.1016/j.drudis.2017.05.015

Cite this

@article{4569ad9f7bc8430bb12009a2bbccdea0,

title = "Lipid–polymer hybrid nanoparticle-mediated therapeutics delivery: advances and challenges",

abstract = "With rapid advances in nanomedicine, lipid–polymer hybrid nanoparticles (LPHNPs) have emerged as promising nanocarriers for several biomedical applications, including therapeutics delivery and biomedical imaging. Significant research has been dedicated to biomimetic or targeting functionalization, as well as controlled and image-guided drug-release capabilities. Despite this research, the clinical translation of LPHNP-mediated therapeutics delivery has progressed incrementally. In this review, we discuss the recent advances in and challenges to the development and application of LPHNPs, present examples to demonstrate the advantages of LPHNPs in therapeutics delivery and imaging applications, and discuss the translational obstacles to LPHNP technology.",

author = "Bose, {Rajendran J.C.} and Rramaswamy Ravikumar and Vengadeshprabu Karuppagounder and Devasier Bennet and Sabarinathan Rangasamy and Thandavarayan, {Rajarajan A.}",

note = "Publisher Copyright: {\textcopyright} 2017",

year = "2017",

month = aug,

doi = "10.1016/j.drudis.2017.05.015",

language = "English (US)",

volume = "22",

pages = "1258--1265",

journal = "Drug Discovery Today",

issn = "1359-6446",

publisher = "Elsevier Limited",

number = "8",

}

TY - JOUR

T1 - Lipid–polymer hybrid nanoparticle-mediated therapeutics delivery

T2 - advances and challenges

AU - Bose, Rajendran J.C.

AU - Ravikumar, Rramaswamy

AU - Karuppagounder, Vengadeshprabu

AU - Bennet, Devasier

AU - Rangasamy, Sabarinathan

AU - Thandavarayan, Rajarajan A.

PY - 2017/8

Y1 - 2017/8

N2 - With rapid advances in nanomedicine, lipid–polymer hybrid nanoparticles (LPHNPs) have emerged as promising nanocarriers for several biomedical applications, including therapeutics delivery and biomedical imaging. Significant research has been dedicated to biomimetic or targeting functionalization, as well as controlled and image-guided drug-release capabilities. Despite this research, the clinical translation of LPHNP-mediated therapeutics delivery has progressed incrementally. In this review, we discuss the recent advances in and challenges to the development and application of LPHNPs, present examples to demonstrate the advantages of LPHNPs in therapeutics delivery and imaging applications, and discuss the translational obstacles to LPHNP technology.

AB - With rapid advances in nanomedicine, lipid–polymer hybrid nanoparticles (LPHNPs) have emerged as promising nanocarriers for several biomedical applications, including therapeutics delivery and biomedical imaging. Significant research has been dedicated to biomimetic or targeting functionalization, as well as controlled and image-guided drug-release capabilities. Despite this research, the clinical translation of LPHNP-mediated therapeutics delivery has progressed incrementally. In this review, we discuss the recent advances in and challenges to the development and application of LPHNPs, present examples to demonstrate the advantages of LPHNPs in therapeutics delivery and imaging applications, and discuss the translational obstacles to LPHNP technology.

UR - http://www.scopus.com/inward/record.url?scp=85021221572&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021221572&partnerID=8YFLogxK

U2 - 10.1016/j.drudis.2017.05.015

DO - 10.1016/j.drudis.2017.05.015

M3 - Review article

C2 - 28600191

AN - SCOPUS:85021221572

SN - 1359-6446

VL - 22

SP - 1258

EP - 1265

JO - Drug Discovery Today

JF - Drug Discovery Today

IS - 8

ER -

Lipid–polymer hybrid nanoparticle-mediated therapeutics delivery: advances and challenges

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this